These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 11448286)

  • 1. Durable HIV treatment benefit despite low-level viremia: reassessing definitions of success or failure.
    Deeks SG
    JAMA; 2001 Jul; 286(2):224-6. PubMed ID: 11448286
    [No Abstract]   [Full Text] [Related]  

  • 2. Prevalence and predictive value of intermittent viremia with combination hiv therapy.
    Havlir DV; Bassett R; Levitan D; Gilbert P; Tebas P; Collier AC; Hirsch MS; Ignacio C; Condra J; Günthard HF; Richman DD; Wong JK
    JAMA; 2001 Jul; 286(2):171-9. PubMed ID: 11448280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIV-1 drug resistance profiles in children and adults with viral load of <50 copies/ml receiving combination therapy.
    Hermankova M; Ray SC; Ruff C; Powell-Davis M; Ingersoll R; D'Aquila RT; Quinn TC; Siliciano JD; Siliciano RF; Persaud D
    JAMA; 2001 Jul; 286(2):196-207. PubMed ID: 11448283
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Viral load assay sensitivity and low level viremia in HAART treated HIV patients.
    Verhofstede C; Van Wanzeele F; Reynaerts J; Mangelschots M; Plum J; Fransen K
    J Clin Virol; 2010 Apr; 47(4):335-9. PubMed ID: 20138803
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patients.
    Rodes B; García F; Gutierrez C; Martinez-Picado J; Aguilera A; Saumoy M; Vallejo A; Domingo P; Dalmau D; Ribas MA; Blanco JL; Pedreira J; Perez-Elias MJ; Leal M; de Mendoza C; Soriano V;
    J Med Virol; 2005 Sep; 77(1):23-8. PubMed ID: 16032728
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Re-emergence of HIV after stopping therapy.
    Chun TW; Davey RT; Engel D; Lane HC; Fauci AS
    Nature; 1999 Oct; 401(6756):874-5. PubMed ID: 10553903
    [No Abstract]   [Full Text] [Related]  

  • 7. Therapies. Confronting the limits of success.
    Cohen J
    Science; 2002 Jun; 296(5577):2320-4. PubMed ID: 12089422
    [No Abstract]   [Full Text] [Related]  

  • 8. [New biological monitoring of HIV infection].
    Morand-Joubert L
    Rev Prat; 1998 Mar; 48(5):472-7. PubMed ID: 9781107
    [No Abstract]   [Full Text] [Related]  

  • 9. [HIV viral dynamic after antiretroviral treatment initiation: is a rapid decay a good pronostic?].
    Delaugerre C
    Pathol Biol (Paris); 2010 Dec; 58(6):403-5. PubMed ID: 19481371
    [No Abstract]   [Full Text] [Related]  

  • 10. Decrease of replicative capacity of HIV isolates after genotypic guided change of therapy.
    Sarmati L; Nicastri E; Montano M; Dori L; Buonomini AR; d'Ettorre G; Gatti F; Parisi SG; Vullo V; Andreoni M
    J Med Virol; 2004 Apr; 72(4):511-6. PubMed ID: 14981751
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Drug resistance in antiretroviral therapy of HIV infection].
    Oette M; Häussinger D
    Med Klin (Munich); 2003 Dec; 98(12):692-9. PubMed ID: 14685670
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential implication of residual viremia in patients on effective antiretroviral therapy.
    Sahu GK
    AIDS Res Hum Retroviruses; 2015 Jan; 31(1):25-35. PubMed ID: 25428885
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Absence of detectable viremia in a perinatally HIV-1-infected teenager after discontinuation of antiretroviral therapy.
    Feeney ME; Tang Y; Rathod A; Kneut C; McIntosh K
    J Allergy Clin Immunol; 2006 Aug; 118(2):324-30. PubMed ID: 16890753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dynamics of intermittent viremia during highly active antiretroviral therapy in patients who initiate therapy during chronic versus acute and early human immunodeficiency virus type 1 infection.
    Di Mascio M; Markowitz M; Louie M; Hurley A; Hogan C; Simon V; Follmann D; Ho DD; Perelson AS
    J Virol; 2004 Oct; 78(19):10566-73. PubMed ID: 15367623
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction therapy with enfuvirtide-based highly active antiretroviral therapy in a patient with acute HIV-1 infection.
    Polk C; Chan-Tack KM; Kopack AM; Amoroso A
    AIDS Patient Care STDS; 2007 Feb; 21(2):75-7. PubMed ID: 17328655
    [No Abstract]   [Full Text] [Related]  

  • 16. Salvage therapy for patients failing their current antiretroviral regimen.
    Albrecht MA
    AIDS Clin Rev; 2000-2001; ():139-91. PubMed ID: 10999220
    [No Abstract]   [Full Text] [Related]  

  • 17. Long-term suppression of plasma viremia with highly active antiretroviral therapy despite virus evolution and very limited selection of drug-resistant genotypes.
    Pariente N; Pernas M; de la Rosa R; Gómez-Mariano G; Fernández G; Rubio A; López M; Benito JM; López-Galíndez C; Leal M; Domingo E; Martinez MA; Mas A
    J Med Virol; 2004 Jul; 73(3):350-61. PubMed ID: 15170628
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AIDS. Boosting immunity to HIV--can the virus help?
    Autran B; Carcelain G
    Science; 2000 Nov; 290(5493):946-9. PubMed ID: 11184735
    [No Abstract]   [Full Text] [Related]  

  • 19. Bias in the estimation of cumulative viremia in cohort studies of HIV-infected individuals.
    Lesosky M; Glass T; Rambau B; Hsiao NY; Abrams EJ; Myer L
    Ann Epidemiol; 2019 Oct; 38():22-27. PubMed ID: 31537405
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The challenge of finding a cure for HIV infection.
    Richman DD; Margolis DM; Delaney M; Greene WC; Hazuda D; Pomerantz RJ
    Science; 2009 Mar; 323(5919):1304-7. PubMed ID: 19265012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.